Amylyx Awaits Key Data Readout for Avexitide in Post-Bariatric Hypoglycemia
Event summary
- Amylyx expects topline data from the Phase 3 LUCIDITY trial of avexitide in late August or early September 2026.
- The company reported a net loss of $43.4 million for Q2 2026, with cash runway extending into 2028.
- Amylyx initiated an Expanded Access Program for avexitide in May 2026 and presented data on AMX0114 at ENCALS 2026.
The big picture
Amylyx is positioning itself as a leader in rare endocrine diseases, with avexitide poised to become the first FDA-approved therapy for post-bariatric hypoglycemia. The company's strategic focus on disease awareness and expanded access programs underscores its commitment to addressing high unmet medical needs. Success in these efforts could validate its pipeline strategy and attract further investment.
What we're watching
- Regulatory Milestones
- Whether the LUCIDITY trial data will support an NDA submission for avexitide in 2027.
- Financial Sustainability
- The pace at which Amylyx can extend its cash runway beyond 2028 amid rising expenses.
- Pipeline Progress
- How AMX0114 and AMX0318 advance through clinical development alongside avexitide.